Hilary Kramer

Hilary Kramer

Hilary Kramer is one of Wall Street’s most successful equity analysts and investment managers, with a reputation as a leading expert on today’s market movements, stock trends and economic outlook.

She received her MBA from the Wharton School at the University of Pennsylvania and her BA from Wellesley College with honors. Hilary Kramer got her start on Wall Street more than two decades ago at Lehman Brothers and Morgan Stanley where she was an analyst in the investment banking group covering natural resources, diversified industrials and energy companies. She was also the chief investment officer of a family office — overseeing a $5.2 billion global private equity and publicly-traded equity fund, and co-vice chairman of the $500 million Ibero-American Partners Fund (1997 to 2003).

In 2004, Hilary’s A&G Capital formed a specialized research arm and investment fund. The GreenTech 21st Century Master Fund focused on companies engaged in alternative energy, clean technologies, environmental infrastructure and services, agricultural and natural resources.

Today, Hilary Kramer is an in-demand commentator whose work often appears in investing publications such as the Wall Street Journal, New York Post, Bloomberg, Business Insider and Reuters and is a regular on CNBC, CNN and the Fox News Channel, providing stock market insight and economic observations.

Hilary Kramer is also the editor of several financial advisory services designed to help individual investors profit from her stock picking talents: Value Authority, GameChangers, Breakout Stocks, High Octane Trader, Absolute Capital Return, Inner Circle and Inner Circle Pro.

Recent Articles

10 Game-Changing Health Care Stocks to Buy

These 10 diverse stocks are likely to improve their earnings and stock prices in 2012. Take a look.

Top Buys for the Novice Investor

If you're a new investor wondering which stocks to buy first, these three names are a great place to start.

Clash of the Coffee Stock Titans: Starbucks Vs. Dunkin’ Brands

For consumers, Starbucks or Dunkin' is just a choice between frilly frappes and average joe. But for investors, one stock offers more bang for the buck.

Bank on This Pair of Biotech Bargains

When it comes to small biotechs, one successful product can send its stock soaring. This pair of companies currently have promising treatments on the horizon.

Handicapping Ford vs. GM Now

GM and Ford have fallen lately in tandem. But if conditions improve, one of these automakers is set up for a bigger rebound.